By Nqobile Dludla JOHANNESBURG, July 21 (Reuters) - South Africa's health regulator is reviewing 12 applications for generic versions of semaglutide, the active ingredient in Novo Nordisk's blockbuster diabetes and weight-loss medicines, it said on Tuesday
However, they are not FDA approved to treat hyperphagia, and most of the newer GLP-1s (Ozempic/semaglutide, Mounjaro/tirzepatide, and others) have not been studied in individuals with PWS
Primary Handling Editor: Jerome Staal, in collaboration with the Nature Medicine team
Reduced hunger and earlier fullness often appear as the dose increases
During Ozempic treatment, understanding how coffee consumption may impact the medications absorption, effectiveness, and blood sugar regulation is important
Whats the histology of alopecia areata